HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

2004 Szydlo, 1997, Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, J Clin Oncol, 15, 1767, 10.1200/JCO.1997.15.5.1767 Zuckerman, 2007, Alternative donor transplantation in acute myeloid leukemia: which source and when?, Curr Opin Hematol, 14, 152, 10.1097/MOH.0b013e328017f64d Anasetti, 1989, Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma, N Engl J Med, 320, 197, 10.1056/NEJM198901263200401 Anasetti, 1990, Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma, Hum Immunol, 29, 79, 10.1016/0198-8859(90)90071-V Kanda, 2003, Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000), Blood, 102, 1541, 10.1182/blood-2003-02-0430 Kernan, 1987, Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes, Transplantation, 43, 842, 10.1097/00007890-198743060-00014 Kernan, 1986, Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease, Blood, 68, 770, 10.1182/blood.V68.3.770.770 Aversa, 1998, Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype, N Engl J Med, 339, 1186, 10.1056/NEJM199810223391702 Aversa, 2005, Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse, J Clin Oncol, 23, 3447, 10.1200/JCO.2005.09.117 Mehta, 2004, Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients, Bone Marrow Transplant, 33, 389, 10.1038/sj.bmt.1704391 Lang, 2004, Long-term outcome after haploidentical stem cell transplantation in children, Blood Cells Mol Dis, 33, 281, 10.1016/j.bcmd.2004.08.017 Waller, 2004, Facilitating T-cell immune reconstitution after haploidentical transplantation in adults, Blood Cells Mol Dis, 33, 233, 10.1016/j.bcmd.2004.08.009 Guinan, 1999, Transplantation of anergic histoincompatible bone marrow allografts, N Engl J Med, 340, 1704, 10.1056/NEJM199906033402202 Dey, 2006, Current status of haploidentical stem cell transplantation, Br J Haematol, 135, 423, 10.1111/j.1365-2141.2006.06300.x Lehnert, 1994, Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration, Bone Marrow Transplant, 13, 473 Mayumi, 1996, Cyclophosphamide-induced immunological tolerance: an overview, Immunobiology, 195, 129, 10.1016/S0171-2985(96)80033-7 Mayumi, 1987, Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease, Transplantation, 44, 286, 10.1097/00007890-198708000-00021 Luznik, 2001, Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide, Blood, 98, 3456, 10.1182/blood.V98.12.3456 Luznik, 2002, Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation, Biol Blood Marrow Transplant, 8, 131, 10.1053/bbmt.2002.v8.pm11939602 O'Donnell, 2002, Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 8, 377, 10.1053/bbmt.2002.v8.pm12171484 Byrd, 2002, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461), Blood, 100, 4325, 10.1182/blood-2002-03-0772 Niederwieser, 2003, Blood, 101, 1620, 10.1182/blood-2002-05-1340 Nomoto, 1992, Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A, J Immunol, 149, 2668, 10.4049/jimmunol.149.8.2668 Crescenzi, 2000, Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants, Cancer Genet Cytogenet, 120, 25, 10.1016/S0165-4608(99)00245-9 Aaltonen, 1993, Clues to the pathogenesis of familial colorectal cancer, Science, 260, 812, 10.1126/science.8484121 Sreenan, 1997, The use of amplified variable number of tandem repeats (VNTR) in the detection of chimerism following bone marrow transplantation. A comparison with restriction fragment length polymorphism (RFLP) by Southern blotting, Am J Clin Pathol, 107, 292, 10.1093/ajcp/107.3.292 Van Deerlin, 2000, Bone marrow engraftment analysis after allogeneic bone marrow transplantation, Clin Lab Med, 20, 197, 10.1016/S0272-2712(18)30083-0 Przepiorka, 1995, 1994 Consensus conference on acute GVHD grading, Bone Marrow Transplant, 15, 825 Sullivan, 1991, Chronic graft-versus-host disease and other late complications of bone marrow transplantation, Semin Hematol, 28, 250 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Gooley, 1999, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O Cox, 1972, Regression models and life-tables (with discussion), J R Stat Soc (B), 34, 187 Junghanss, 2002, Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study, Blood, 99, 1978, 10.1182/blood.V99.6.1978 Marr, 2002, Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients, Clin Infect Dis, 34, 909, 10.1086/339202 Upton, 2007, Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality, Clin Infect Dis, 44, 531, 10.1086/510592 Mielcarek, 2003, Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, 102, 756, 10.1182/blood-2002-08-2628 Crawley, 2005, Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT, Blood, 2004 Bruno, 2007, A Comparison of allografting with autografting for newly diagnosed myeloma, N Engl J Med, 356, 1110, 10.1056/NEJMoa065464 Giralt, 2007, Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program, Biol Blood Marrow Transplant, 13, 844, 10.1016/j.bbmt.2007.03.011 Santos, 1965, A comparison of the effects of selected cytotoxic agents on allogeneic skin graft survival in rats, Bull Johns Hopkins Hosp, 116, 327 Berenbaum MC. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 200, 84. 1963. Colson, 1995, A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers, J Immunol, 155, 4179, 10.4049/jimmunol.155.9.4179 Owens, 1971, The effect of cytotoxic drugs on graft-versus-host disease in mice, Transplantation, 11, 378, 10.1097/00007890-197104000-00004 Glucksberg, 1972, Chemotherapy of established graft-versus-host disease in mice, Transplantation, 13, 300, 10.1097/00007890-197203000-00016 Storb, 1970, Treatment of canine graft-versus-host disease with methotrexate and cyclo-phosphamide following bone marrow transplantation from histoincompatible donors, Transplantation, 10, 165, 10.1097/00007890-197008000-00003 Santos, 1987, Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized, double-blind study in patients undergoing allogeneic marrow transplantation, Clin Transplant, 1, 21 Mayumi, 1986, Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination, Transplant Proc, 18, 363 Cheshier, 1999, In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells, Proc Natl Acad Sci USA, 96, 3120, 10.1073/pnas.96.6.3120 Jones, 1995, Assessment of aldehyde dehydrogenase in viable cells, Blood, 85, 2742, 10.1182/blood.V85.10.2742.bloodjournal85102742 Luznik, 2007, Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT), Biol Blood Marrow Transplant, 13, 4, 10.1016/j.bbmt.2006.12.008 Giaccone, 2005, Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation, Blood, 106, 4381, 10.1182/blood-2005-06-2217 Sykes, 1999, Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation, Lancet, 353, 1755, 10.1016/S0140-6736(98)11135-2 Spitzer, 2003, Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies, Transplantation, 75, 1748, 10.1097/01.TP.0000064211.23536.AD Rizzieri, 2007, Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution, J Clin Oncol, 25, 690, 10.1200/JCO.2006.07.0953 Fukuda, 2003, Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning, Blood, 102, 827, 10.1182/blood-2003-02-0456 Lu, 2006, Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, Blood, 107, 3065, 10.1182/blood-2005-05-2146 Laughlin, 2004, Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia, N Engl J Med, 351, 2265, 10.1056/NEJMoa041276 Arcese, 2006, Unrelated cord blood transplants in adults with hematologic malignancies, Haematologica, 91, 223 Barker, 2005, Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy, Blood, 105, 1343, 10.1182/blood-2004-07-2717 Miyakoshi, 2004, Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases, Clin Cancer Res, 10, 3586, 10.1158/1078-0432.CCR-03-0754 Brunstein, 2007, Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease, Blood, 110, 3064, 10.1182/blood-2007-04-067215 Barker, 2003, Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning, Blood, 102, 1915, 10.1182/blood-2002-11-3337 Ballen, 2007, Double unrelated reduced-intensity umbilical cord blood transplantation in adults, Biol Blood Marrow Transplant, 13, 82, 10.1016/j.bbmt.2006.08.041